Transforming growth factor beta secretion from primary breast cancer fibroblasts.
Transforming growth factor beta (TGF-beta) is a hormonally regulated growth inhibitor with autocrine and/or paracrine functions in human breast cancer. In vivo, enhanced immunohistochemical staining of extracellular TGF-beta 1 has been detected around stromal fibroblasts in response to the antiestrogen treatment. We have investigated the effects of tamoxifen on the production of TGF-beta by primary human breast fibroblast cultures in serum-free medium. Highly variable levels of mainly latent TGF-beta 1 were detected in conditioned media from both tumor and normal tissue derived fibroblasts. Hydroxy-tamoxifen was shown to increase latent TGF-beta 1 secretion in three of the eight tumor tissue-derived fibroblast cultures. Such effect of hydroxy-tamoxifen was not observed in fibroblast cultures established from normal adjacent breast tissue.
van Roozendaal
C E
CE
Department of Medical Oncology, Dr Daniel den Hoed Cancer Center, Rotterdam, The Netherlands.
Klijn
J G
JG
van Ooijen
B
B
Claassen
C
C
Eggermont
A M
AM
Henzen-Logmans
S C
SC
Foekens
J A
JA
D000818:Animals; D001681:Biological Assay; D001943:Breast Neoplasms / Q000378:metabolism* / Q000473:pathology; D002455:Cell Division; D002460:Cell Line; D003470:Culture Media; D017077:Culture Media, Conditioned; D005347:Fibroblasts / Q000378:metabolism; D006801:Humans; D008168:Lung; D008907:Mink; D017154:Stromal Cells / Q000378:metabolism; D013629:Tamoxifen / Q000494:pharmacology; D016212:Transforming Growth Factor beta / Q000096:biosynthesis / Q000378:metabolism*; D014407:Tumor Cells, Cultured
D003470:Culture Media; D017077:Culture Media, Conditioned; D016212:Transforming Growth Factor beta; D013629:Tamoxifen